Compare Microsoft (MSFT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microsoft vs Zimmer Biomet Holdings Inc — how do they compare? Microsoft trades at $492.42 (market cap $3.67T), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Microsoft is far larger — about 204.2× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.02%). Which is the better fit depends on your goals.
| MSFT | ZBH | |
|---|---|---|
Market Cap | $3.67T | $17.97B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $104.26 |
52-Week Low | $352.83 | $79.58 |
Enterprise Value | $3.65T | $25.04B |
Dividend Yield | 0.74% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $493.95, down 1.15% on the day, with a bullish technical signal and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $4.74 exceeding expectations of $4.24. Revenue growth is steady, reaching $281.72B in 2025, supported by a net income margin of 40.31% and a high ROE of 34.04%. News highlights AI leadership and Azure momentum, though capital expenditure concerns persist.
Outlook remains positive with an 80.49% analyst buy rating and a consensus price target of $560.43, implying significant upside. Risks include competitive pressures in AI, high valuation multiples like a P/E of 27.52, and macroeconomic volatility. The stock's strength in cloud computing and consistent profitability underpins long-term growth potential.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
